Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.

LANXESS to showcase Biosecurity Solutions at EuroTier 2022

The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products

Solvay partners with Ostium in single-use surgical instruments material recycling

Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.

Lupin receives tentative approval from USFDA for Doxycycline Capsules

Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US

Astec LifeSciences plan Capex of Rs. 300 - 350 Cr

R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab

Ami Organics Q2 FY23 revenue up 20.2%; Profit up 9%

The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23

SeQuent Scientific to acquire 100% stake in Tineta Pharma

The acquisition is for an enterprise value of Rs. 218 crores

Apollo Hospital launches Vertigo and Balance Disorder clinic in Hyderabad

Zydus receives EIR with VAI from USFDA for Moraiya facility

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)

Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%